Cipher Pharmaceuticals Inc. (TSE:CPH - Free Report) NASDAQ: CPHR - Stock analysts at Leede Financial reduced their FY2025 earnings estimates for shares of Cipher Pharmaceuticals in a research note issued on Wednesday, March 19th. Leede Financial analyst D. Loe now expects that the company will earn $0.87 per share for the year, down from their prior estimate of $0.93. The consensus estimate for Cipher Pharmaceuticals' current full-year earnings is $1.29 per share. Leede Financial also issued estimates for Cipher Pharmaceuticals' FY2026 earnings at $1.00 EPS.
Cipher Pharmaceuticals Stock Down 2.6 %
Shares of CPH stock traded down C$0.33 during trading hours on Friday, reaching C$12.32. The company had a trading volume of 22,036 shares, compared to its average volume of 36,434. The company has a market capitalization of C$221.18 million, a P/E ratio of 13.61 and a beta of 1.20. The company has a debt-to-equity ratio of 41.22, a quick ratio of 2.67 and a current ratio of 2.00. Cipher Pharmaceuticals has a twelve month low of C$7.90 and a twelve month high of C$19.69. The stock's fifty day simple moving average is C$12.85 and its 200 day simple moving average is C$14.38.
Insiders Place Their Bets
In other news, Director Harold Morton Wolkin sold 3,500 shares of the firm's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of C$13.49, for a total transaction of C$47,215.00. 42.00% of the stock is owned by company insiders.
Cipher Pharmaceuticals Company Profile
(
Get Free Report)
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company's geographical segments include Canada and the United States.
Featured Articles
Before you consider Cipher Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cipher Pharmaceuticals wasn't on the list.
While Cipher Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
